{"id":"every-week-ivmp-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Mood changes"},{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Osteoporosis (with chronic use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IVMP is a synthetic glucocorticoid administered intravenously, typically in high doses on a weekly schedule. It works by binding to glucocorticoid receptors in immune cells, suppressing T-cell and B-cell function, reducing pro-inflammatory cytokine production, and stabilizing cell membranes to reduce inflammation. This broad immunosuppressive effect makes it useful in autoimmune and inflammatory conditions.","oneSentence":"Intravenous methylprednisolone (IVMP) is a corticosteroid that suppresses immune and inflammatory responses by inhibiting cytokine production and immune cell activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:46:04.739Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis (relapse treatment)"},{"name":"Autoimmune inflammatory conditions"},{"name":"Severe inflammatory or autoimmune disorders"}]},"trialDetails":[{"nctId":"NCT07420296","phase":"PHASE4","title":"Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-01-01","conditions":"Neuromyelitis Optica Spectrum Disorders (NMOSD)","enrollment":198},{"nctId":"NCT03542279","phase":"NA","title":"CPI Combination Therapy for Autoimmune Encephalitis","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2020-11-25","conditions":"Autoimmune Encephalitis","enrollment":70},{"nctId":"NCT06497374","phase":"PHASE2","title":"FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2024-07-05","conditions":"Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder","enrollment":63},{"nctId":"NCT02411838","phase":"NA","title":"Calorie Restriction in Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2014-02","conditions":"Multiple Sclerosis","enrollment":17},{"nctId":"NCT03667157","phase":"PHASE4","title":"Liver Function After Intravenous Methylprednisolone Administration","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2012-01-01","conditions":"Graves Disease, Graves Ophthalmopathy, Liver Diseases","enrollment":68}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"every week IVMP therapy","genericName":"every week IVMP therapy","companyName":"Medical University of Warsaw","companyId":"medical-university-of-warsaw","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intravenous methylprednisolone (IVMP) is a corticosteroid that suppresses immune and inflammatory responses by inhibiting cytokine production and immune cell activation. Used for Multiple sclerosis (relapse treatment), Autoimmune inflammatory conditions, Severe inflammatory or autoimmune disorders.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}